EcoDrugPlus

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSSMAG00000000112
Gene Symbol: PIK3CB
1 Cross references
216 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Alpha

Ensembl ID : ENSSMAG00000019551
Gene Symbol: PIK3CA
2 Cross references
181 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Delta

Ensembl ID : ENSSMAG00000018115
Gene Symbol: PIK3CD
1 Cross references
211 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSSMAG00000008617
Gene Symbol: PDE10A
3 Cross references
205 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSSMAG00000009999
Gene Symbol: PDE3A
1 Cross references
195 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSSMAG00000021404
Gene Symbol: PDE3B
1 Cross references
217 Possible Orthologues:

Phosphodiesterase 4b, Camp-Specific A

Ensembl ID : ENSSMAG00000020743
Gene Symbol: PDE4BA
2 Cross references
227 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSSMAG00000001598
Gene Symbol: PDE4D
3 Cross references
235 Possible Orthologues:

Phosphodiesterase 5a, Cgmp-Specific, B

Ensembl ID : ENSSMAG00000004989
Gene Symbol: PDE5AB
3 Cross references
221 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSSMAG00000015092
Gene Symbol: PDE7A
1 Cross references
227 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSSMAG00000017545
Gene Symbol: PDE9A
3 Cross references
185 Possible Orthologues:

Phosphoinositide 3-Kinase Regulatory Subunit 5-Like

Ensembl ID : ENSSMAG00000003654
Gene Symbol: LOC118288552
2 Cross references
185 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).